Arbele and BioAI Health Ink pact to develop prototype

Arbele, a leading innovator in biopharmaceutical and biotechnology focused on targeting cadherin-17 (CDH17), has announced a strategic collaboration in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs).

Partnership aims advancing the quantification and prognostic prediction of CDH17 expression in tumor tissue and the surrounding tumor immune microenvironment, are expected to accelerate the development of precise companion diagnostics and effective clinical trials for the treatment of advanced cancer patients.

The strategic alliance with BioAI Health will develop a prototype of an immunohistochemistry (IHC)-based quantification algorithm. Leveraging the PredictX platform to develop AI-based models using Arbele’s clinical trial data on colorectal cancer (CRC) biomarker screening, we join force to establish a gold standard companion diagnostic test for anti-CDH17 therapies for patient selection and prediction of clinical outcomes.

“By partnering with Arbele, we are excited to apply our novel AI platform and expertise to accelerate the development of innovative treatment options for gastrointestinal cancers,” said Thomas Colarusso, CEO of BioAI. “This partnership underscores our commitment to revolutionizing personalized medicine through cutting-edge machine learning.”

“BioAI’s machine learning capabilities offer a transformative approach to biomarker identification and patient stratification through predicting CDH17 expression and its spatial interaction with immune cells in tumor microenvironment,” said Dr John Luk, CEO of Arbele. “This collaboration is a critical step in guiding us the uses of the right treatment modalities and/or therapeutic regimens, thereby improving outcomes for patients with high mortality cancers."